Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2020 | Defibrotide treatment in VOD/SOS patients

Mohamad Mohty • 7 Dec 2020

ASH 2020

General Defibrotide

DEFIFrance

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the DEFIFrance study. This study collected real-world data on the safety and effectiveness of defibrotide in France in patients with veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after hematopoietic stem cell transplantation (HSCT). The efficacy and safety observed in this study support the utility of defibrotide for treating severe/very severe VOD/SOS post-HSCT in a real-world setting. Its findings highlight the importance of prompt diagnosis and continued treatment until full resolution of symptoms is achieved. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Looking forward to COMy 2024: celebrating 10 years

Mohamad Mohty • 17 Apr 2024

Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD

Mohamad Mohty • 17 Apr 2024

Comparing alloSCT outcomes in secondary and de-novo acute lymphoblastic leukemia

Mohamad Mohty • 15 Feb 2024

The evolving role of autoSCT in the age of CAR-T for multiple myeloma: current & future perspectives

Mohamad Mohty • 15 Feb 2024

Related Videos

The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024

Natacha Bolaños • 16 Apr 2024

Distinguishing late-onset neutropenia from classical primary neutropenia

Carlo Dufour • 15 Apr 2024

The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract

James Ferrara • 16 Apr 2024

The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives

Claire Horgan • 15 Apr 2024